Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies

Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies
Author :
Publisher : National Academies Press
Total Pages : 94
Release :
ISBN-10 : 9780309368605
ISBN-13 : 030936860X
Rating : 4/5 (05 Downloads)

Book Synopsis Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies by : Institute of Medicine

Download or read book Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies written by Institute of Medicine and published by National Academies Press. This book was released on 2015-06-01 with total page 94 pages. Available in PDF, EPUB and Kindle. Book excerpt: A long-held goal in oncology has been to develop therapies that target the specific abnormalities in each patient's cancer rather than simply treating cancers based on the tissue of origin. In the past decade, advances in technology have enabled researchers to relatively quickly and inexpensively determine, in minute detail, the genetic makeup of tumors. Although relatively few targeted cancer therapies are currently available in the clinic and it is not yet clear whether all cancers are driven by genetic changes that can be targeted, there is widespread optimism in the cancer community that this new ability to assess the genetic abnormalities in tumors will ultimately lead to better cancer treatments and improved patient outcomes. Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies is the summary of a workshop convened in November 2014 by the Institute of Medicine's National Cancer Policy Forum to discuss recent trends in the development and implementation of molecularly targeted cancer therapies and explore potential policy actions to address specific challenges. This report highlights the presentations and discussions at the workshop.


Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies Related Books

Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies
Language: en
Pages: 94
Authors: Institute of Medicine
Categories: Medical
Type: BOOK - Published: 2015-06-01 - Publisher: National Academies Press

DOWNLOAD EBOOK

A long-held goal in oncology has been to develop therapies that target the specific abnormalities in each patient's cancer rather than simply treating cancers b
Biomarker Tests for Molecularly Targeted Therapies
Language: en
Pages: 293
Authors: National Academies of Sciences, Engineering, and Medicine
Categories: Medical
Type: BOOK - Published: 2016-06-30 - Publisher: National Academies Press

DOWNLOAD EBOOK

Every patient is unique, and the evolving field of precision medicine aims to ensure the delivery of the right treatment to the right patient at the right time.
Cancer Biomarkers
Language: en
Pages: 256
Authors: Committee on Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment
Categories: Medical
Type: BOOK - Published: 2007-03-30 - Publisher: National Academies Press

DOWNLOAD EBOOK

Many cancer patients are diagnosed at a stage in which the cancer is too far advanced to be cured, and most cancer treatments are effective in only a minority o
The Drug Development Paradigm in Oncology
Language: en
Pages: 145
Authors: National Academies of Sciences, Engineering, and Medicine
Categories: Medical
Type: BOOK - Published: 2018-02-12 - Publisher: National Academies Press

DOWNLOAD EBOOK

Advances in cancer research have led to an improved understanding of the molecular mechanisms underpinning the development of cancer and how the immune system r
Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies
Language: en
Pages: 85
Authors: Sharyl J. Nass
Categories:
Type: BOOK - Published: 2015 - Publisher:

DOWNLOAD EBOOK

A long-held goal in oncology has been to develop therapies that target the specific abnormalities in each patient's cancer rather than simply treating cancers b